Rena Lambert, DO
Obesity Medicine · Allentown, PANPI 1639371032
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 74 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Novo Nordisk at 28.2% of the total. Reporting peaked in 2022 at $545 and has fallen 77.1% since, to $125 in 2025.
Across 74 payments — averaging $26.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$543
- Boehringer Ingelheim$522
- Lilly USA, LLC$292
- Esperion Therapeutics, Inc.$108
- Johnson & Johnson$90
- Phadia US Inc.$74
- plus $300 from 10 others
What the payments were for
- Food & beverage$1,928100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 13 | $543 |
| Boehringer Ingelheim | 22 | $522 |
| Lilly USA, LLC | 13 | $292 |
| Esperion Therapeutics, Inc. | 1 | $108 |
| Johnson & Johnson | 6 | $90 |
| Phadia US Inc. | 3 | $74 |
| Sanofi-aventis U.S. LLC | 3 | $60 |
| Merck | 2 | $42 |
| Pfizer | 2 | $37 |
| AstraZeneca | 2 | $37 |
| GSK | 2 | $33 |
| Abbott | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Bayer | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few obesity medicine providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,152 |
| Levothyroxine Sodium | 23 | $158 |
| Atorvastatin Calcium | 15 | $124 |
| Alcohol SwabsAlcohol Antiseptic Pads | 20 | $98 |
Paid to pharmacies, not to this prescriber.
Other obesity medicine in Allentown
- Sunil DanielAllentown$9K
- Robin SchroederAllentown$954
- Kia WestAllentown$310
- Asima AhmadAllentown$220
- Monica BrandauAllentown$32
- Margarita McDonaldAmbler$111K
- Joseph McPheeLancaster$9K
- Paul BaughmanHarrisburg$3K
- Lawrence WiegerLancaster$678
- Charles SeltzerPhiladelphia$623
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.